3ZO0 Stock Chart & Stats
€5.09
€0.00(0.00%)
At close: 4:00 PM EDT
€5.09
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.09 - €5.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€6.48M
Enterprise Value-€4.05M
Total Cash (Recent Filing)€10.66M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-1.56
Next Earnings
Nov 18, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding5,559,405
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-0.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.10Price Target Upside196.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free balance sheet reduces fixed financial obligations and preserves flexibility while the higher TTM equity cushion improves resilience versus prior years. This gives Acurx more room to prioritize clinical development, although it does not offset its ongoing operating losses.
FDA Regulatory ProgressFDA engagement on a potential single pivotal Phase III pathway improves regulatory clarity for ibezapolstat and may streamline development if future evidence is robust. The accepted product branding and retained Fast Track and QIDP designations further support the program’s strategic positioning.
Funded PATHFINDER TrialA fully funded trial with imminent enrollment creates a defined clinical milestone and advances evidence generation in recurrent CDI. FDA recognition of PATHFINDER as significant supportive data could improve the program’s registration prospects and inform later pivotal development.
Bears Say
Pre-Revenue And Unprofitable ModelAcurx has no established product revenue and continues to report losses, so it lacks operating leverage and internally generated funding. The improved TTM loss still leaves earnings meaningfully negative, keeping future profitability dependent on successful clinical development and commercialization.
Persistent Cash BurnNegative operating and free cash flow across all periods shows the business is not self-funding. The unusually large reported outflows in 2025 and TTM also make cash needs harder to forecast, increasing dependence on external capital as development programs advance.
ASPIRE Funding UncertaintyASPIRE, the planned international Phase III pivotal trial, cannot proceed on the stated plan without substantial additional funding. With resources covering PATHFINDER and operations for about one year, financing and execution remain central constraints on the program’s timeline.
Acurx Pharmaceuticals News
3ZO0 FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was €5.09 and its highest was €5.20 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is €6.48M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 42 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -€0.472 earnings per share for the quarter, missing the consensus estimate of -€0.335 by -€0.136.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.34.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 5,559,405 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -€0.472 in its last earnings report, missing expectations of -€0.335. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:3ZO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
3ZO0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful regulatory, scientific and IP progress (FDA engagement on a potential single pivotal Phase III pathway, trademark allowance for Syfbezi, fully funded PATHFINDER, manufacturing readiness, partnerships, and strengthened cash vs year-end) while also highlighting material challenges: the need to secure substantial funding to run a large international Phase III (ASPIRE), a limited stated runway (~1 year), rising R&D costs tied to trial startup, ongoing operating losses, and potential dilution from financings. On balance the call emphasized significant program and regulatory momentum but also clear near-term financing and execution risks.View all DE:3ZO0 earnings summaries3ZO0 Stock 12 Month Forecast
Average Price Target
€15.10
▲(196.63% Upside)
Technical Analysis
Soligenix
―
GeoVax Labs
―
Cocrystal Pharma
―
Citius Pharmaceuticals
―
Aligos Therapeutics
―